Zimmer Biomet vs Bristol Myers Squibb
Side-by-side comparison of AI visibility scores, market position, and capabilities
Zimmer Biomet (ZBH) reported ~$7.7B revenue in FY2024. Leading maker of orthopedic implants for knee and hip replacement surgeries, with robotics and digital surgery platforms. HQ: Warsaw, IN.
About
Zimmer Biomet Holdings, Inc. is one of the world's largest musculoskeletal healthcare companies, designing, manufacturing, and distributing orthopedic implants, spinal devices, dental implants, and surgical instrumentation. The company's core products are total knee and total hip replacement systems — the implants that allow surgeons to replace arthritic or damaged joints, enabling millions of patients to regain mobility and reduce chronic pain. Formed through Zimmer Holdings' $13.4 billion acquisition of Biomet in 2015, the company serves over 25 million patients annually.
Princeton NJ biopharma (NYSE: BMY) at $48.3B 2024 revenue; Eliquis $13.3B, Opdivo $9.2B, Cobenfy schizophrenia launch; $23B acquisitions (Karuna+Mirati+RayzeBio) building next pipeline vs. Pfizer and Merck.
About
Bristol Myers Squibb (BMS) is a Princeton, New Jersey-based global biopharmaceutical company — publicly traded on the New York Stock Exchange (NYSE: BMY) as an S&P 500 Healthcare component — discovering, developing, and delivering innovative medicines for serious diseases including cancer, cardiovascular disease, immunology, and neuroscience through approximately 34,000 employees worldwide. In fiscal year 2024, BMS reported total revenue of $48.3 billion (+7% year-over-year), with its Growth Portfolio generating $22.6 billion (+17%), driven by blockbusters Eliquis ($13.3B anticoagulant), Opdivo ($9.2B immuno-oncology), and Revlimid ($5.8B multiple myeloma). New product revenue surged 77% to $3.6 billion, led by schizophrenia treatment Cobenfy (formerly KarXT), CAR-T therapy Breyanzi, anemia drug Reblozyl, and Opdualag checkpoint inhibitor combination. CEO Dr. Christopher Boerner assumed leadership in November 2023, accelerating BMS's pipeline expansion through three transformative acquisitions in 2024: Karuna Therapeutics ($14B, Cobenfy/KarXT for schizophrenia and Alzheimer's agitation), Mirati Therapeutics ($4.8B, KRAS-targeted oncology), and RayzeBio ($4.1B, radiopharmaceutical cancer therapy).
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Integrations
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.